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Abstract: Long chain fatty acids influence inflammation through a variety of mechanisms; 
many of these are mediated by, or at least associated with, changes in fatty acid 
composition of cell membranes. Changes in these compositions can modify membrane 
fluidity, cell signaling leading to altered gene expression, and the pattern of lipid mediator 
production. Cell involved in the inflammatory response are typically rich in the n-6 fatty 
acid arachidonic acid, but the contents of arachidonic acid and of the n-3 fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can be altered through oral 
administration of EPA and DHA. Eicosanoids produced from arachidonic acid have roles 
in inflammation. EPA also gives rise to eicosanoids and these often have differing 
properties from those of arachidonic acid-derived eicosanoids. EPA and DHA give rise to 
newly discovered resolvins which are anti-inflammatory and inflammation resolving. 
Increased membrane content of EPA and DHA (and decreased arachidonic acid content) 
results in a changed pattern of production of eicosanoids and resolvins. Changing the fatty 
acid composition of cells involved in the inflammatory response also affects production of 
peptide mediators of inflammation (adhesion molecules, cytokines etc.). Thus, the fatty 
acid composition of cells involved in the inflammatory response influences their function; 
the contents of arachidonic acid, EPA and DHA appear to be especially important. The 
anti-inflammatory effects of marine n-3 PUFAs suggest that they may be useful as 
therapeutic agents in disorders with an inflammatory component.  
Keywords:  leukocyte; neutrophil; macrophage; monocyte; eicosanoid; cytokine; 
interleukin; fish oil 
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1. Introduction  
Inflammation is a normal defense mechanism that protects the host from infection and other insults; 
it initiates pathogen killing as well as tissue repair processes and helps to restore homeostasis at 
infected or damaged sites. It is typified by redness, swelling, heat, pain and loss of function, and 
involves interactions amongst many cell types and the production of, and responses to, a number of 
chemical mediators. Where an inflammatory response does occur, it is normally well regulated in order 
that it does not cause excessive damage to the host, is self-limiting and resolves rapidly. This self-
regulation involves the activation of negative feedback mechanisms such as the secretion of anti-
inflammatory mediators, inhibition of pro-inflammatory signaling cascades, shedding of receptors for 
inflammatory mediators, and activation of regulatory cells. As such, when controlled properly, 
regulated inflammatory responses are essential to remain healthy and maintain homeostasis. 
Pathological inflammation involves a loss of tolerance and/or of regulatory processes [1]. Where this 
becomes excessive, irreparable damage to host tissues and disease can occur. Irrespective of the cause 
of the inflammation, the response involves four major events: 
  An increased blood supply to the site of inflammation; 
  Increased capillary permeability caused by retraction of endothelial cells. This permits larger 
molecules, not normally capable of traversing the endothelium, to do so and thus delivers soluble 
mediators to the site of inflammation; 
  Leukocyte migration from the capillaries into the surrounding tissue. This is promoted by release 
of chemoattractants from the site of inflammation and by the upregulation of adhesion molecules 
on the endothelium. Once in the tissue the leukocytes move to the site of inflammation; 
  Release of mediators from leukocytes at the site of inflammation. These may include lipid 
mediators (e.g., prostaglandins (PGs), leukotrienes (LTs)), peptide mediators (e.g., cytokines), 
reactive oxygen species (e.g., superoxide), amino acid derivatives (e.g., histamine), and enzymes 
(e.g., matrix proteases) depending upon the cell type involved, the nature of the inflammatory 
stimulus, the anatomical site involved, and the stage during the inflammatory response. These 
mediators normally would play a role in host defense, but when produced inappropriately or in 
an unregulated fashion they can cause damage to host tissues, leading to disease. Several of these 
mediators may act to amplify the inflammatory process acting, for example, as chemoattractants. 
Some of the inflammatory mediators may escape the inflammatory site into the circulation and 
from there they can exert systemic effects. For example, the cytokine interleukin (IL)-6 induces 
hepatic synthesis of the acute phase protein C-reactive protein, while the cytokine tumour 
necrosis factor (TNF)- elicits metabolic effects within skeletal muscle, adipose tissue and bone.  
 
2. Fatty Acid Composition of Cells Involved in Inflammation and its Modification by Marine n-3 
Fatty Acids 
 
Polyunsaturated fatty acids (PUFAs) are important constituents of the phospholipids of all cell 
membranes. Laboratory animals that have been maintained on standard chow have a high content of 
arachidonic acid (20:4n-6) and low contents of eicosapentaenoic acid (20:5n-3; EPA) and 
docosahexaenoic acid (22:6n-3; DHA) in the bulk phospholipids of tissue lymphocytes [2,3], Nutrients 2010, 2                                       
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peritoneal macrophages [4-8], alveolar macrophages [9,10], Kupffer cells [10], and alveolar 
neutrophils [11-13]. Feeding laboratory animals a diet containing fish oil, which provides EPA and 
DHA, results in a higher content of these fatty acids in lymphocytes [3], macrophages [4-7,9,10], 
Kupffer cells [10] and neutrophils [11-13]; typically enrichment in marine n-3 PUFAs is accompanied 
by a decrease in content of arachidonic acid. The bulk phospholipids of blood cells representing those 
that become involved in inflammatory responses (e.g., neutrophils, lymphocytes, monocytes) and 
collected from humans consuming typical Western diets contain about 10 to 20% of fatty acids as 
arachidonic acid, with about 0.5 to 1% EPA and about 2 to 4% DHA [14-25], although there are 
differences between the different phospholipid classes in terms of the content of these fatty acids [16]. 
The fatty acid composition of these cells can be modified by increasing intake of marine n-3 fatty  
acids [14-21,23-25]. This occurs in a dose response fashion [25] and over a period of days to weeks, 
with a new steady-state composition reached within about 4 weeks (Figure 1). Typically the increase 
in content of n-3 PUFAs occurs at the expense of n-6 PUFAs, especially arachidonic acid.  
Figure 1. Time course of incorporation of EPA and DHA into human blood mononuclear 
cells. Healthy subjects supplemented their diet with fish oil capsules providing 2.1 g EPA 
plus 1.1 g DHA per day for a period of 12 weeks. Blood mononuclear cell phospholipids 
were isolated at 0, 4, 8 and 12 weeks and their fatty acid composition determined by gas 
chromatography. Data are mean ± SEM from 8 subjects and are from Yaqoob et al. [19]. 
 
 
3. Mechanisms by which Polyunsaturated Fatty Acids can Influence Inflammatory Cell Function 
 
PUFAs can influence inflammatory cell function, and so inflammatory processes, by a variety of 
mechanisms as follows: 
  PUFA intake can influence complex lipid, lipoprotein, metabolite and hormone concentrations 
that in turn influence inflammation; Nutrients 2010, 2                                       
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  Non-esterified PUFAs can act directly on inflammatory cells via surface or intracellular “fatty 
acid receptors” – the latter may include transcription factors like peroxisome proliferator 
activated receptors (PPARs); 
  PUFAs can be oxidized (enzymatically or non-enzymatically) and the oxidized derivatives can 
act directly on inflammatory cells via surface or intracellular receptors – oxidation can occur to 
the non-esterified form of the PUFA or to PUFAs esterified into more complex lipids including 
circulating or cell membrane phospholipids and intact lipoproteins such as low density 
lipoprotein (LDL);  
  PUFAs can be incorporated into the phospholipids of inflammatory cell membranes (as 
described above). Here they play important roles assuring the correct environment for 
membrane protein function, maintaining membrane order (“fluidity”) and influencing lipid raft 
formation [26]. Membrane phospholipids are substrates for the generation of second 
messengers like diacylglycerol and it has been demonstrated that the fatty acid composition of 
such second messengers, which is determined by that of the precursor phospholipid, can 
influence their activity [27]. In addition, membrane phospholipids are substrates for the release 
of (non-esterfied) PUFAs intracellularly – the released PUFAs can act as signaling molecules, 
ligands (or precursors of ligands) for transcription factors, or precursors for biosynthesis of 
lipid mediators which are involved in regulation of many cell and tissue responses, including 
aspects of inflammation and immunity (see below). Thus, changes in membrane phospholipid 
fatty acid composition, as described above, can influence the function of cells involved in 
inflammation via: 
o   alterations in the physical properties of the membrane such as membrane order and raft 
structure; 
o  effects on cell signaling pathways, either through modifying the expression, activity or 
avidity of membrane receptors or modifying intracellular signal transduction 
mechanisms that lead to altered transcription factor activity and changes in gene 
expression; 
o  alterations in the pattern of lipid mediators produced, with the different mediators 
having different biological activities and potencies (see below).  
The multitude of potential mechanisms involved and their complexity has made it difficult to fully 
understand the actions of PUFAs within inflammatory processes. This difficulty has been further 
compounded by the variety of experimental approaches that have been used, including the method of 
presentation of PUFAs of interest to inflammatory cells in order to study their effects. For example, 
many in vitro studies have exposed cells to non-esterified fatty acids, often at concentrations that 
might not be achieved physiologically. Thus, effects of non-esterified PUFAs on responses of 
lymphocytes [2], monocytes [28], macrophages [8,29-33], neutrophils [34-36] and endothelial   
cells [37-39] have been demonstrated. These effects may involve a direct effect of the non-esterified 
PUFA or of an oxidized derivative of the PUFA [40-42] or they may be secondary to incorporation of 
the PUFA into cell membrane phospholipids. Physiologically, the concentration of non-esterified n-3 
PUFAs (and also arachidonic acid) is quite low. These fatty acids are carried in the bloodstream at 
much higher concentrations in more complex lipids (triglycerides, phospholipds, cholesteryl esters) 
within lipoproteins. Many of the cell types involved in inflammatory responses express lipoprotein Nutrients 2010, 2                                       
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receptors (e.g., LDL receptor, very low density lipoprotein receptor, scavenger receptors) and so are 
able to take up intact lipoproteins, subsequently utilising the fatty acid components. Thus, lipoproteins 
may affect inflammatory cell function [43,44], perhaps due to their component fatty acids. 
Inflammatory cells may also access fatty acids from lipoproteins by hydrolysing them extracellularly 
as has been demonstrated for macrophages [45] and lymphocytes [46]. Thus, cells involved in 
inflammatory processes are exposed to fatty acids, including PUFAs, in many different forms, and they 
may access fatty acids from their environment by a variety of mechanisms. The effect of the form of 
presentation of PUFAs to inflammatory cells can be examined in the cell culture setting and studies to 
date indicate that non-esterified fatty acids [28-39], complex lipids like triglycerides [46], intact 
lipoproteins [44], and oxidized forms of fatty acids and other lipids [40-42] all influence inflammatory 
cell responses, frequently with different effects or different potencies of n-6 and n-3 PUFAs.   
Following increased dietary intake of marine n-3 PUFAs their concentrations increase in complex 
lipids within the bloodstream (triglycerides, phospholipids, cholesteryl esters), as well as within the 
membrane phospholipids of cells and tissues including those involved in inflammatory responses (see 
above), and there is a small increase in their concentration within the circulating non-esterfied fatty 
acid pool; the latter increase is small because circulating non-esterfied fatty acids derive principally 
from adipose tissue triglyceride breakdown and adipose tissue triglycerides contain very little EPA and 
DHA. Thus, following increased intake of EPA and DHA, both the cells involved in inflammation and 
their extracellular environment (e.g., blood plasma) are enriched in those fatty acids, so that the n-3 
PUFA enriched inflammatory cells will be in contact with n-3 PUFA-rich complex lipids and 
lipoproteins. Many studies have examined the effect of increased intake of marine n-3 PUFAs on the 
function of cells typically involved in inflammation taken from the bloodstream (neutrophils, 
eosinophils, monocytes, lymphocytes) or, in the case of animal studies tissues and subsequently 
cultured. In many, probably most, cases the in vivo situation is not maintained during the ex vivo 
culture period, in that the n-3 PUFA enriched cells are maintained in an environment that is different 
from that to which they were exposed in vivo i.e., to an n-3 PUFA poor environment. Thus, the in vivo 
situation is not replicated in the ex vivo setting. This hampers the full interpretation of the findings of 
such research.   
 
4. Lipid Mediators: Biosynthesis, Roles in Inflammation, and the Impact of Marine n-3 fatty 
acids  
 
4.1. Eicosanoids Generated from Arachidonic Acid 
 
Eicosanoids are key mediators and regulators of inflammation and immunity and are generated 
from 20 carbon PUFAs. Eicosanoids, which include PGs, thromboxanes, LTs and other oxidised 
derivatives, are generated from arachidonic acid by the metabolic processes summarized in Figure 2. 
Eicosanoids are involved in modulating the intensity and duration of inflammatory responses [47,48], 
have cell- and stimulus-specific sources and frequently have opposing effects. Thus, the overall 
physiological (or pathophysiological) outcome will depend upon the cells present, the nature of the 
stimulus, the timing of eicosanoid generation, the concentrations of different eicosanoids generated 
and the sensitivity of target cells and tissues to the eicosanoids generated. Because of the relatively Nutrients 2010, 2                                       
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high amount of arachidonic acid in membrane phospholipids of cells involved in inflammation, this 
fatty acid is typically the major precursor for eicosanoid mediators, which are produced in greatly 
increased amounts upon cellular stimulation. Thus, amongst the mix of eicosanoids produced, those 
synthesized from arachidonic acid (e.g., PGE2 and LTB4) predominate although the exact eicosanoid 
profile depends upon the cell type concerned (e.g., neutrophils and mast cells produce a lot of PGD2 
whereas monocytes produce a lot of PGE2) and the nature of the stimulus; the profile will also change 
over time as the nature of the response to the stimulus alters. In general arachidonic acid-derived 
eicosanoids act in a pro-inflammatory way, although this is an over-simplification since it is now 
recognised that PGE2, for example, has both pro- and anti-inflammatory effects, and that another 
eicosanoid derived from arachidonic acid, lipoxin A4, is anti-inflammatory [49-52]. 
Figure 2 Outline of the pathway of eicosanoid biosynthesis from arachidonic acid. COX, 
cyclooxygenase; HETE, hydroxyeicosatetraenoic acid; HpETE, 
hydroperoxyeicosatetraenoic acid; LOX, lipoxygenase; LT, leukotriene; LX, lipoxin; 
oxoETE, oxoeicosatetraenoic acid; PG, prostaglandin; TX, thromboxane.  
 
 
4.2. Fatty Acid Modification of Eicosanoid Profiles 
 
Animal studies have shown a direct relationship between arachidonic acid content of inflammatory 
cell phospholipids and ability of those cells to produce PGE2
 [53], such that PGE2 production is 
increased by arachidonic acid feeding [53] and decreased by EPA or DHA feeding [53-55]. It is well 
documented that PGE2 and 4 series-LT production by human inflammatory cells can be significantly 
decreased by fish oil supplementation of the diet for a period of weeks to months [14-16,18,56,57].  
EPA is also a substrate for the cyclooxygenase and lipoxygenase enzymes that produce eicosanoids, 
but the mediators produced have a different structure from the arachidonic acid-derived mediators, and 
this influences their potency. Increased generation of 5-series LTs has been demonstrated using Nutrients 2010, 2                                       
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macrophages from fish oil-fed mice [55] and neutrophils from humans supplemented with oral fish oil 
for several weeks [14-16]. The functional significance of the generation of eicosanoids from EPA is 
that EPA-derived mediators are often much less biologically active than those produced from 
arachidonic acid (Figure 3). For example EPA-derived LTB5 is 10- to 100-fold less potent as a 
neutrophil chemoattractant compared with LTB4 [58,59]. Furthermore, EPA-derived eicosanoids may 
antagonise the action of those produced from arachidonic acid, as was recently demonstrated for PGD3 
vs. PGD2 [60]. However, in some cases arachidonic acid-derived and EPA-derived eicosanoids appear 
to behave with similar potency (e.g., inhibition of TNF- production by monocytes [61,62]).  
Figure 3 General overview of synthesis and actions of lipid mediators produced from 
arachidonic acid, EPA and DHA. COX, cyclooxygenase; LOX, lipoxygenase; LT, 
leukotriene; PG, prostaglandin.  
 
 
4.3. Resolvins: Novel Anti-Inflammatory and Inflammation Resolving Mediators Produced from EPA 
and DHA 
 
EPA and DHA also give rise to resolvins and related compounds (e.g., protectins) through pathways 
involving cyclooxygenase and lipoxygenase enzymes (Figure 4) [63-65]. These mediators have been 
demonstrated in cell culture and animal feeding studies to be anti-inflammatory and inflammation 
resolving (Figure 3). For example, resolvin E1, resolvin D1 and protectin D1 all inhibit 
transendothelial migration of neutrophils, so preventing neutrophilic infiltration at sites of 
inflammation, resolvin D1 inhibits IL-1 production, and protectin D1 inhibits TNF and IL-1 
production (see [65] for references). The role of resolvins and related compounds may be very 
important because resolution of inflammation is important in shutting off the ongoing inflammatory 
process and in limiting tissue damage. 
 
5. Influence of Marine n-3 Fatty Acids on Leukocyte Chemotaxis 
 
A number of dietary supplementation studies with fish oil have demonstrated a time-dependent 
decrease in chemotaxis of human neutrophils and monocytes towards various chemoattractants 
including LTB4, bacterial peptides and human serum [14-16,66-68]. Both the distance of cell migration 
and the number of cells migrating were decreased. Despite the high dose of marine n-3 PUFAs used in 
many of these studies (3.1 to 14.4 g EPA+DHA/day), a dose response study by Schmidt et al. [69] 
suggests that near-maximum inhibition of chemotaxis occurs at an intake of 1.3 g EPA+DHA/day. Nutrients 2010, 2                                       
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Some studies report no effect of n-3 PUFAs on neutrophil chemotaxis [20,70,71]. An explanation for 
this lack of effect with regard to one of these studies [70] may be that the dose of EPA+DHA used was 
too low to be active (0.55 g EPA+DHA/day). However the other two studies [20,71] used higher doses 
of EPA+DHA, but in both cases this was a DHA-rich preparation with little EPA being provided. If 
this is the explanation for the lack of effect, then this suggests that the anti-chemotactic effects of fish 
oil might be due to EPA rather than DHA. There have been no studies attempting to discriminate the 
effects of EPA and DHA on chemotaxis. The mechanism by which n-3 PUFAs inhibit chemotaxis is 
not clear but may relate to reduced expression or antagonism of receptors for chemoattractants. 
Figure 4 Outline of the pathway of synthesis of resolvins and related mediators from EPA 
and DHA. COX, cyclooxygenase; HpDHA, hydroperoxydocosahexaenoic acid; HpEPE, 
hydroperoxyeicosapentaenoic acid; LOX, lipoxygenase; LT, leukotriene; PG, 
prostaglandin; Rv, resolvin; TX, thromboxane 
 
 
6. Influence of Marine n-3 Fatty Acids on Adhesion Molecules and Adhesive Interactions 
 
Cell culture [28,37-39] and animal feeding studies [72,73] report decreased expression of some 
adhesion molecules on the surface of monocytes [28], macrophages [72], lymphocytes [73] or 
endothelial cells [37-39]
 following exposure to marine n-3 PUFAs. In some cases this was shown to 
result in decreased adhesion between leukocytes and endothelial cells. Supplementing the diet of 
healthy humans with fish oil providing about 1.5 g EPA+DHA/day resulted in a lower level of 
expression of ICAM-1 on the surface of blood monocytes stimulated ex vivo with interferon-
 [74]. 
Dietary fish oil providing 1.1 g EPA+DHA/day was found to decrease circulating levels of soluble 
VCAM-1 in elderly subjects [75], but it is not clear if this represents decreased surface expression of 
VCAM-1. 
 
7. Influence of Marine n-3 Fatty Acids on Inflammatory Cytokines 
 
7.1. Transcription Factors Involved in Regulating Inflammatory Gene Expression 
 
In addition to effects on inflammation mediated by changes in the pattern of eicosanoids and other 
lipid mediators produced, marine n-3 PUFAs have also been shown to alter the production of 
inflammatory proteins including chemokines, cytokines, growth factors and matrix proteases. This Nutrients 2010, 2                                       
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effect may be mediated by altered activation of key transcription factors involved in regulating 
inflammatory gene expression. Two transcription factors that are likely to play a role in inflammation 
are nuclear factor  B (NFB) and PPAR-. NFB is the principal transcription factor involved in 
upregulation of inflammatory cytokine, adhesion molecule and cyclooxygenase-2 genes [76,77]. NFB 
is activated as a result of a signalling cascade triggered by extracellular inflammatory stimuli and 
involving phosphorylation of an inhibitory subunit (inhibitory subunit of NFB (IB)) which then 
allows translocation of the remaining NFB dimer to the nucleus [78]. The second transcription factor, 
PPAR-, is believed to act in an anti-inflammatory manner. While PPAR- directly regulates 
inflammatory gene expression, it also interferes with the activation of NFB creating an intriguing 
interaction between these two transcription factors [79]. Both NFB and PPAR- may be regulated by 
n-3 PUFAs. 
 
7.2. Fatty Acid Modulation of Inflammatory Cytokine Production and of Transcription Factor 
Activation 
 
EPA and DHA inhibited endotoxin-stimulated production of IL-6 and IL-8 by cultured human 
endothelial cells [38,80] and EPA or fish oil inhibited endotoxin-induced TNF- production by 
cultured monocytes [29,30]. EPA or fish oil decreased endotoxin-induced activation of NFB in 
human monocytes and this was associated with decreased IB phosphorylation [31], perhaps due to 
decreased activation of mitogen-activated protein kinases [32]. These observations suggest effects of 
marine n-3 PUFAs on inflammatory gene expression via inhibition of activation of the transcription 
factor NFB. 
Animal feeding studies with fish oil support the observations made in cell culture with respect to 
the effects of marine n-3 PUFAs on NFB activation and inflammatory cytokine production. 
Compared with feeding corn oil, fish oil lowered NFB activation in endotoxin-activated murine 
spleen lymphocytes [81]. Feeding fish oil to mice decreased ex vivo production of TNF-, IL-1 and 
IL-6 by endotoxin-stimulated macrophages [54,82,83]. Several studies in healthy human volunteers 
involving supplementation of the diet with fish oil have demonstrated decreased production of TNF-, 
IL-1, IL-6 and various growth factors by endotoxin-stimulated monocytes or mononuclear cells (a 
mixture of lymphocytes and monocytes) [15,18,56,84-86], although not all studies confirm this effect. 
Some of the studies that fail to show an effect of n-3 PUFAs on cytokine production have provided < 2 
g EPA+DHA/day [70,87-90], which may be an insufficient dose, although others have provided higher 
doses [19,24,91-94]. It is not clear what the reason for these discrepancies in the literature is, but 
technical factors are likely to be contributing factors, as discussed in detail elsewhere [95]. The relative 
contributions of EPA and DHA might also be important in determining the effect of fish oil. One other 
factor that has recently been identified is polymorphisms in genes affecting cytokine production [96]. 
In this study it was found that the effect of dietary fish oil upon cytokine production by human 
mononuclear cells was dependent upon the nature of the -308 TNF- and the +252 TNF- 
polymorphisms.  
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8. Anti-Inflammatory Effects of Marine n-3 Fatty Acids Suggest a Therapeutic Value 
 
Inflammation is an overt or covert component of numerous human conditions and diseases   
(Table 1) [1]. Although the inflammation may afflict different body compartments, one common 
characteristic of these conditions and diseases is excessive or inappropriate production of 
inflammatory mediators including eicosanoids and cytokines [1]. The foregoing discussion has 
highlighted that marine n-3 PUFAs can act in a number of ways to reduce inflammation. They: 
  decrease production of eicosanoid mediators from arachidonic acid, many of which have pro-
inflammatory roles; 
  increase production of weakly inflammatory or anti-inflammatory eicosanoids from EPA; 
  increase production of anti-inflammatory and inflammation resolving resolvins from EPA and 
DHA; 
  decrease chemotactic responses of leukocytes;  
  decrease adhesion molecule expression on leukocytes and on endothelial cells and decrease 
intercellular adhesive interactions; 
  decrease production of pro-inflammatory cytokines and other pro-inflammatory proteins induced 
via the NFB system. 
The roles marine n-3 PUFAs in shaping and regulating inflammatory processes and responses 
suggest that the level of exposure to these fatty acids might be important in determining the 
development and severity of inflammatory diseases. The recognition that marine n-3 PUFAs have anti-
inflammatory actions has lead to the idea that supplementation of the diet of patients with 
inflammatory diseases may be of clinical benefit. Each of the diseases or conditions listed in Table 1 is 
a possible therapeutic target for marine n-3 PUFAs. Perhaps unsurprisingly, supplementation trials 
have been conducted in most of these diseases. Those conducted in patients with rheumatoid arthritis 
appear to be the most successful with most trials reporting several clinical benefits [97]; these benefits 
are supported by meta-analyses of the available data [98,99]. Studies in patients with inflammatory 
bowel diseases (Crohn’s disease and ulcerative colitis) provide equivocal findings with some showing 
some benefits and others not [100,101]. Likewise studies conducted in patients with asthma do not 
provide a clear picture; most studies conducted in adults do not show a clinical benefit, while there are 
indications of benefits of marine n-3 PUFAs in children and adolescents, although there are few 
studies in those groups [102]. An extension of the latter studies is recent work in pregnancy which 
shows an impact of marine n-3 PUFAs on the maternal and foetal immune system [103-105], that may 
reduce risk of development of allergic type diseases in infancy [104] and childhood [106]. Although 
this is an emerging area with few published studies at present, the possibility of an early effect of 
marine n-3 PUFAs on immune maturation hints at an important, novel role for these fatty acids in early 
development [102,107,108]. In most other inflammatory diseases and conditions there are too few 
studies to draw a clear conclusion of the possible efficacy of marine n-3 PUFAs as a treatment. One 
exception to this may be related to cardiovascular disease morbidity and mortality. There is evidence 
that marine n-3 PUFAs slow the progress of atherosclerosis [109,110], which has an inflammatory 
component [111,112]. Further, marine n-3 PUFAs decrease mortality due to cardiovascular   
disease [113,114]; this may be, in part, due to stabilization of atherosclerotic plaques against   
rupture [115], which again has an inflammatory component [112,116]. Thus, the anti-inflammatory Nutrients 2010, 2                                       
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effects of marine n-3 PUFAs may contribute to their protective actions towards atherosclerosis, plaque 
rupture and cardiovascular mortality.  
Table 1. List of diseases and conditions with an inflammatory component in which marine 
n-3 fatty acids might be of benefit. Note: this list is not exhaustive. 
Disease/condition 
Rheumatoid arthritis 
Crohn’s disease 
Ulcerative colitis 
Lupus 
Type-1 diabetes 
Cystic fibrosis 
Childhood asthma 
Adult asthma 
Allergic disease 
Chronic obstructive pulmonary disease 
Psoriasis 
Multiple sclerosis 
Atherosclerosis 
Acute cardiovascular events 
Obesity 
Neurodegenerative diseases of ageing 
Systemic inflammatory response to surgery, trauma and critical illness  
 
The dose of marine n-3 PUFAs required to prevent or to treat different inflammatory conditions is 
not clear, although it is evident that the anti-inflammatory effects of these fatty acids are dose-
dependent [25]. As alluded to above, studies in healthy human volunteers suggest that an intake of >2 
g EPA+DHA/day is required to affect inflammatory processes. There are few dose response studies 
investigating the effect of marine n-3 PUFAs in patients with inflammatory conditions. Studies in 
rheumatoid arthritis have used 1.5 to 7 g EPA+DHA/day (average about 3.5 g/day) and have been of 
long duration (3 to 12 months), with effects becoming apparent after some months [97]. One study that 
used two doses of n-3 PUFAS [117] reported that both doses induced benefit, but that the effect was 
seen earlier with the higher dose. If doses of 2 g, or even more, of EPA+DHA per day are required 
before an anti-inflammatory effect is seen, it is possible that some studies in patients fail to show a 
benefit because they have used an insufficient dose, or been of insufficient duration. It is not known 
whether different doses of marine n-3 PUFAs are required to treat different inflammatory conditions, 
but this is a possibility because the precise nature of the inflammation (i.e., the cells, mediators and 
signaling systems involved) will differ from condition to condition [1] and it may be that these 
different components of inflammation show different sensitivities to n-3 PUFAs.  
 
9. Conclusions 
 
Fatty acids influence inflammation through a variety of mechanisms; many of these are mediated 
by, or at least associated with, changes in fatty acid composition of cell membranes. Changes in these Nutrients 2010, 2                                       
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compositions can modify membrane fluidity, cell signaling leading to altered gene expression, and the 
pattern of lipid mediator production. Cells involved in the inflammatory response are typically rich in 
the n-6 fatty acid arachidonic acid, but the contents of arachidonic acid and of the n-3 fatty acids EPA 
and DHA can be altered through oral administration of EPA and DHA. Eicosanoids produced from 
arachidonic acid have roles in inflammation. EPA also gives rise to eicosanoids and these may have 
differing properties from those of arachidonic acid-derived eicosanoids. EPA and DHA give rise to 
newly discovered resolvins which are anti-inflammatory and inflammation resolving. Increased 
membrane content of EPA and DHA (and decreased arachidonic acid content) results in a changed 
pattern of production of eicosanoids and probably also of resolvins. Changing the fatty acid 
composition of inflammatory cells also affects production of peptide mediators of inflammation 
(adhesion molecules, cytokines etc.). Thus, the fatty acid composition of human inflammatory cells 
influences their function; the contents of arachidonic acid, EPA and DHA appear to be especially 
important. As a result of their anti-inflammatory actions marine n-3 PUFAs have therapeutic efficacy 
in rheumatoid arthritis, although benefits in other inflammatory diseases and conditions have not been 
unequivocally demonstrated. The anti-inflammatory effects of marine n-3 PUFAs may contribute to 
their protective actions towards atherosclerosis, plaque rupture and cardiovascular mortality. 
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